New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
A Phase III trial found that adding a personalised mRNA vaccine to pembrolizumab reduced the risk of melanoma returning or causing death among people whose high-risk tumours had been removed. The findings could broaden treatment options after surgery, though the vaccine remains under investigation and is not intended to prevent melanoma.
The INTerpath-001 trial included 1,137 participants, followed for an average of 24.6 months. Recurrence-free survival was 82.2 per cent with the combination, compared with 70 per cent with pembrolizumab alone; the combination also lowered the risk of the cancer spreading by 38 per cent. The vaccine was tailored using mutations identified in each patient’s tumour, and reported side effects included fever, fatigue and injection-site pain.
In short
- Personalised mRNA vaccine cut recurrence or death risk by 42 per cent.
- 82.2 per cent remained recurrence-free with the combination treatment.
- The vaccine is still being tested and needs regulatory approval.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The results suggest a personalised mRNA vaccine may improve outcomes when added to pembrolizumab after surgery for high-risk melanoma, with higher recurrence-free survival in the trial. If further evidence confirms the benefit, the combination could give patients and clinicians another treatment option tailored to the tumour’s mutations.
The case against
The vaccine remains under investigation, and the reported follow-up of about two years does not establish how durable the benefit is or whether it improves overall survival. Its added side effects, cost and practical demands of tailoring a vaccine for each patient also matter when weighing it against pembrolizumab alone.
Explained simply
Melanoma is a type of skin cancer. When it is found at high risk of returning or spreading, doctors may remove the tumour with surgery and give further treatment to reduce that risk.
Pembrolizumab is a medicine that helps the immune system recognise and attack cancer cells. A personalised mRNA vaccine is designed from mutations in a person’s tumour, with the aim of helping their immune system target that cancer.
The trial compared pembrolizumab alone with pembrolizumab plus the vaccine in people whose high-risk melanoma had been removed. The vaccine is still being investigated as treatment after surgery; it is not intended to prevent melanoma.